Preclinical research plays a critical role in the drug development pipeline, and selecting the right models and study designs can significantly impact the success of therapeutic discovery. Biocytogen invites you to an engaging Lunch & Learn seminar where Dr. Yanzuo Liu will provide a insightful presentation on “Biocytogen Company Overview: Gene Targeting, Drug Target Humanized Models, Pharmacology Services, Fully Human Antibody Platforms”.
This seminar will provide a deep dive into the importance of gene targethumanized mice, pharmacological disease models, and RenBiologics and their application in autoimmune and inflammatory diseases, and beyond. Attendees will gain valuable insights into experimental design, troubleshooting common challenges, and leveraging innovative technologies to generate more predictive and translational preclinical data. As a global leader ingene-editing and in vivo pharmacology, Biocytogen provides a comprehensive suite of humanized and knockout models, along with integrated preclinical solutions to accelerate drug discovery.
Don’t miss this opportunity to connect with fellow researchers, exchange ideas, and discover how Biocytogen’s expertise can help streamline your preclinical studies and fast-track your path to clinical success.
Why Attend?
Insightful Presentation: Learn about the services Biocytogen provides in accelerating drug development and improving research outcomes.
Engaging Discussions:Participate in discussions on the latest advancements and challenges in biotech and pharmaceuticals.
Delicious Lunch:Enjoy a carefully curated lunch box featuring local delicacies and international flavors.
RSVP Now
Spaces are limited, and this is a popular event. Secure your spot today by registering now.
About Biocytogen
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
